Publications
2018
Engineered synthetic antibodies as probes to quantify the energetic contributions of ligand binding to conformational changes in proteins.,
Mukherjee, Somnath, Griffin Dionne H., Horn James R., Rizk Shahir S., Nocula-Lugowska Malgorzata, Malmqvist Magnus, Kim Sangwoo S., and Kossiakoff Anthony A.
, J Biol Chem, 2018 02 23, Volume 293, Issue 8, p.2815-2828, (2018)
2017
Targeted rescue of cancer-associated IDH1 mutant activity using an engineered synthetic antibody.,
Rizk, Shahir S., Mukherjee Somnath, Koide Akiko, Koide Shohei, and Kossiakoff Anthony A.
, Sci Rep, 2017 04 03, Volume 7, Issue 1, p.556, (2017)
Publications
- Characterization of synthetic antigen binding fragments targeting Toc75 for the isolation of TOC in A. thaliana and P. sativum.
- Development of a universal nanobody-binding Fab module for fiducial-assisted cryo-EM studies of membrane proteins.
- Development, structure, and mechanism of synthetic antibodies that target claudin and Clostridium perfringens enterotoxin complexes.
- Engineering of a synthetic antibody fragment for structural and functional studies of K+ channels.
- Isoform- and ligand-specific modulation of the adhesion GPCR ADGRL3/Latrophilin3 by a synthetic binder.
- Quaternary structure independent folding of voltage-gated ion channel pore domain subunits.
- Structural basis for assembly and lipid-mediated gating of LRRC8A:C volume-regulated anion channels.
- Structure of an AMPK complex in an inactive, ATP-bound state.
- Structure of human NTCP reveals the basis of recognition and sodium-driven transport of bile salts into the liver.
- Structure, sequon recognition and mechanism of tryptophan C-mannosyltransferase.
- Structures of ABCB4 provide insight into phosphatidylcholine translocation.
- Structures of atypical chemokine receptor 3 reveal the basis for its promiscuity and signaling bias.
- Synthetic Antibodies Detect Distinct Cellular States of Chromosome Passenger Complex Proteins.
- Targeting a proteolytic neoepitope on CUB domain containing protein 1 (CDCP1) for RAS-driven cancers.